Development of a gene-expression panel predictive of local recurrence, metastasis, and overall survival in intermediate- to high-risk cutaneous squamous cell carcinoma: A cohort study - 18/02/26
Abstract |
Background |
Cutaneous squamous cell carcinoma (cSCC) is one of the most common malignancies and carries risks of metastasis and death. Current staging systems have a poor positive predictive value in identifying cSCCs at risk of metastasis or patient death. Gene expression profiling (GEP) in high-risk cSCC has demonstrated promise in predicting poor outcomes.
Objective |
To develop and optimize a novel GEP panel using a patient cohort with stage-matched, outcome-differentiated cSCC based upon 183 functionally relevant genes identified through previous multi-omic work using the NanoString platform on 186 tumors in 183 patients.
Results |
Fourteen genes were used to generate a risk score for metastasis, resulting in an area under the curve (AUC) score of 82.0% (95% CI: 75.9% to 88.2%), overall accuracy of 75.3%, sensitivity of 65.1%, and specificity of 80.5%, respectively. Three genes were found to be predictive of local recurrence, resulting in an AUC score of 74.7% (95% CI: 63.8% to 85.6%), overall accuracy of 69.4%, sensitivity of 73.9%, and specificity of 68.7%, respectively. Eight genes were associated with overall survival 1.28 (95% CI: 1.13 to 1.46, P < 0.001) after adjusting for age, immunosuppressant use, and metastasis status.
Conclusion |
Our GEP panel demonstrates the potential to predict outcomes in at-risk cSCC.
Le texte complet de cet article est disponible en PDF.Key words : cancer genetics, carcinogenesis, clinical dermatology, gene expression profile, genomics, metastasis, squamous cell carcinoma
Abbreviations used : AJCC, AUC, BWH, cSCC, GEP, LR, LASSO, PMet, PNoMet, NPV, OS, PPV, QC
Plan
| Authors Leibovit-Reiben and Stockard contributed equally to this article. |
|
| Funding sources: This work was supported by the Innovation Accelerator Awards from the Mayo Clinic Office of Translation to Practice. This work was also supported by Desert Mountain Cares and the Flinn Foundation ( 23-12148 ). The content is solely the responsibility of the authors and does not necessarily represent the official views of Mayo Clinic. Dr Cañueto is partially supported by the Instituto de Salud Carlos III (ISCIII), grants PI21/1207 and PI24/00396 (cofunded by the European Union ). |
|
| Patient consent: Informed consent is not applicable, as this is a retrospective study accessing archived samples. |
|
| IRB approval status: Approved by the Mayo Clinic Institutional Review Board IRB 21-012833. |
|
| Data availability: All RNA NanoString data that support the findings of this study are available in Supplementary Table I, available via Mendeley 1 at that can be accessed through the TableS1.xlsx file on Mendeley. |
Vol 94 - N° 3
P. 843-851 - mars 2026 Retour au numéro
Article précédent
- Ultraviolet-induced fluorescent dermoscopy for the diagnosis of skin tumors: A multicenter study
- Cristian Navarrete-Dechent, Pawel Pietkiewicz, Alvaro Abarzua-Araya, Rosario Agüero, Stephen W. Dusza, Julien Anriot, Pablo Vargas-Mora, Javiera Garcés, Sofía Villagrán, Sergio Bustos, Sebastián González-Valdés, Samuel Ibañez, Manuela Boleira, Natalia Jaimes, David Swanson, Leonel Hidalgo, Katherine Droppelmann, Consuelo Cardenas, Pablo Uribe, Ashfaq A. Marghoob
- Population differences in Merkel cell carcinoma by virus status and anatomic site: A multi-cohort analysis including institutional, SEER, and NCDB data
- Mackenzie R. Martin, Serena M. Vilasi, Yoshine Saito, Noreen Mohsin, Jordan E. Jarvis, Patrick Hallaert, Danielle J. Reed, Lingling Miao, Jacob T. Tribble, Elizabeth K. Cahoon, Ruth M. Pfeiffer, Krista Lachance, Rima Kulikauskas, Paul Nghiem, Isaac Brownell
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?